BCAL Diagnostics Targets November Launch After Breast Test Validation
BDX: $0.084 +5.00% · MC: $22M
BCAL Diagnostics completed clinical validation of BREASTESTplus 2 for women aged 30 and over across all breast densities, with a launch targeted for November subject to accreditation and operational readiness. Avantect Multicancer is now available at select Sydney and Melbourne locations, while preparations continue for a broader rollout. BCAL also increased its strategic interest in Genetic Signatures to approximately 18%, acquiring additional shares for $2 million.

Comments